ASCO 2023 | Future directions in the field of targeted therapies for urothelial carcinoma

Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, touches on future directions in the development of targeted therapies for patients with urothelial carcinoma, highlighting the recent approval of enfortumab vedotin in combination with pembrolizumab by the U.S FDA, as well as subsequent unanswered questions. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.